Introduction
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AlzeCure Pharma AB, H1 2020
Pipeline by Amorepacific Corp, H1 2020
Pipeline by AntalGenics SL, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by Bsense Bio Therapeutics Ltd, H1 2020
Pipeline by Centrexion Therapeutics Corp, H1 2020
Pipeline by Cmxtwenty, H1 2020
Pipeline by Concentric Analgesics Inc, H1 2020
Pipeline by GB Sciences Inc, H1 2020
Pipeline by GBSciences Inc, H1 2020
Pipeline by Grunenthal GmbH, H1 2020
Pipeline by GW Pharmaceuticals Plc, H1 2020
Pipeline by Interventional Analgesix Inc, H1 2020
Pipeline by Ion Channel Pharmacology LLC, H1 2020
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
Pipeline by Medifron DBT Co Ltd, H1 2020
Pipeline by Mestex AG, H1 2020
Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oblique Therapeutics AB, H1 2020
Pipeline by Pila Pharma AB, H1 2020
Pipeline by Revive Therapeutics Ltd, H1 2020
Pipeline by Scopus BioPharma Inc, H1 2020
Pipeline by Serentrix LLC, H1 2020
Pipeline by Sorrento Therapeutics Inc, H1 2020
Pipeline by Sylentis SAU, H1 2020
Pipeline by Vitality Biopharma Inc, H1 2020
Pipeline by Winston Pharmaceuticals Inc, H1 2020
Pipeline by Young BioPharma LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Dormant Products, H1 2020 (Contd..6), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• AlzeCure Pharma AB
• Amorepacific Corp
• AntalGenics SL
• Astellas Pharma Inc
• Bsense Bio Therapeutics Ltd
• Centrexion Therapeutics Corp
• Cmxtwenty
• Concentric Analgesics Inc
• GB Sciences Inc
• GBSciences Inc
• Grunenthal GmbH
• GW Pharmaceuticals Plc
• Interventional Analgesix Inc
• Ion Channel Pharmacology LLC
• Jeil Pharmaceutical Co Ltd
• Medifron DBT Co Ltd
• Mestex AG
• Neurim Pharmaceuticals Ltd
• Novartis AG
• Oblique Therapeutics AB
• Pila Pharma AB
• Revive Therapeutics Ltd
• Scopus BioPharma Inc
• Serentrix LLC
• Sorrento Therapeutics Inc
• Sylentis SAU
• Vitality Biopharma Inc
• Winston Pharmaceuticals Inc
• Young BioPharma LLC